NASDAQ
TG Therapeutics, Inc. (TGTX)
♥ 404 Thanks from members
TG Therapeutics exhibits strong bullish momentum driven by surging Briumvi sales and upwardly revised 2026 revenue guidance, despite a Q2 earnings per share miss resulting from heavy manufacturing and pipeline investments.